RxDoctor Payments Data

Jyotsna Ganta, MD

Internal Medicine · Reno, NVNPI 1528402260

Payments from drug & device makers

$3,773in general payments, 2019–2025

Across 176 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$480
  • GSK$353
  • Pfizer$330
  • Novo Nordisk$318
  • Astellas Pharma US Inc$315
  • Amgen$303
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$3,773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,773 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$91,605
Medicare patients
307
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol59$79,941
JardianceEmpagliflozin60$77,039
OzempicSemaglutide51$59,674
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$58,712
TrulicityDulaglutide27$39,013
MounjaroTirzepatide27$33,699
EliquisApixaban26$32,638
TradjentaLinagliptin11$16,640
XareltoRivaroxaban18$16,275
MyrbetriqMirabegron12$16,139
VascepaIcosapent Ethyl14$10,067
Atorvastatin Calcium267$4,736
Rosuvastatin Calcium203$4,236
Lisinopril314$2,614
Albuterol Sulfate HfaAlbuterol Sulfate82$2,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$131$93,67971 claims
AstraZenecaFarxiga$480$79,94159 claims
Lilly USA, LLCTrulicity, Mounjaro$254$72,71254 claims
Novo NordiskOzempic$318$59,67451 claims
GSKTrelegy Ellipta$353$58,71249 claims
PfizerEliquis$330$32,63826 claims
Johnson & JohnsonXarelto$94$16,27518 claims
Astellas Pharma US IncMyrbetriq$315$16,13912 claims
AbbVieSynthroid$200$82714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →